Zoetis (NYSE:ZTS) Given News Impact Rating of 0.11

Media coverage about Zoetis (NYSE:ZTS) has trended somewhat positive on Wednesday, Accern Sentiment reports. The research firm identifies positive and negative news coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Zoetis earned a daily sentiment score of 0.11 on Accern’s scale. Accern also assigned media coverage about the company an impact score of 46.8769804321075 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.

These are some of the news headlines that may have effected Accern’s scoring:

Several analysts have weighed in on ZTS shares. Stifel Nicolaus reiterated a “buy” rating and issued a $65.00 price objective on shares of Zoetis in a research note on Friday, July 21st. Deutsche Bank AG cut shares of Zoetis from a “buy” rating to a “hold” rating and set a $65.00 price objective for the company. in a research note on Tuesday, July 25th. Goldman Sachs Group, Inc. (The) reiterated a “neutral” rating and issued a $62.00 price objective on shares of Zoetis in a research note on Monday, August 7th. Cantor Fitzgerald set a $75.00 price objective on shares of Zoetis and gave the stock a “buy” rating in a research note on Monday, August 14th. Finally, Cowen and Company set a $70.00 price objective on shares of Zoetis and gave the stock a “buy” rating in a research note on Thursday, August 24th. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating and twelve have issued a buy rating to the company’s stock. Zoetis currently has a consensus rating of “Buy” and an average target price of $67.06.

Zoetis (ZTS) opened at $69.90 on Wednesday. The company has a market cap of $33,564.42, a P/E ratio of 31.60, a PEG ratio of 2.01 and a beta of 1.02. The company has a quick ratio of 1.95, a current ratio of 2.80 and a debt-to-equity ratio of 2.45. Zoetis has a 12-month low of $48.24 and a 12-month high of $70.48.

Zoetis (NYSE:ZTS) last announced its quarterly earnings results on Thursday, November 2nd. The company reported $0.65 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.63 by $0.02. The company had revenue of $1.35 billion for the quarter, compared to analyst estimates of $1.32 billion. Zoetis had a net margin of 18.29% and a return on equity of 62.39%. The firm’s revenue was up 8.5% on a year-over-year basis. During the same period in the previous year, the firm posted $0.52 EPS. sell-side analysts predict that Zoetis will post 2.36 earnings per share for the current fiscal year.

The business also recently declared a quarterly dividend, which will be paid on Friday, December 1st. Investors of record on Thursday, November 9th will be issued a dividend of $0.105 per share. This represents a $0.42 annualized dividend and a dividend yield of 0.60%. The ex-dividend date is Wednesday, November 8th. Zoetis’s dividend payout ratio (DPR) is presently 22.11%.

TRADEMARK VIOLATION WARNING: This piece of content was reported by Week Herald and is the property of of Week Herald. If you are reading this piece of content on another publication, it was stolen and republished in violation of U.S. and international trademark and copyright laws. The correct version of this piece of content can be viewed at https://weekherald.com/2017/11/15/zoetis-zts-earns-media-sentiment-rating-of-0-11.html.

About Zoetis

Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a business, commercializing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals), and within five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.

Insider Buying and Selling by Quarter for Zoetis (NYSE:ZTS)

Receive News & Ratings for Zoetis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply